DE2837168A1
(de)
|
1978-08-25 |
1980-03-06 |
Blutspendedienst Dt Rote Kreuz |
Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten immunglobulinloesung
|
US4362661A
(en)
|
1979-08-09 |
1982-12-07 |
Teijin Limited |
Immunoglobulin composition having a high monomer content, and process for production thereof
|
US4360457A
(en)
|
1979-08-30 |
1982-11-23 |
Teijin Limited |
S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
|
US4374763A
(en)
|
1979-09-17 |
1983-02-22 |
Morishita Pharmaceutical Co., Ltd. |
Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
|
US4396608A
(en)
|
1981-08-24 |
1983-08-02 |
Cutter Laboratories |
Intravenously injectable immune serum globulin
|
US5702699A
(en)
|
1982-09-23 |
1997-12-30 |
Cetus Corporation |
Process for the recovery of lipophilic proteins
|
US4681713A
(en)
|
1984-03-15 |
1987-07-21 |
Toyo Boseki Kabushiki Kaisha |
Method of making a hollow fiber membrane for dialysis
|
US4597966A
(en)
|
1985-01-09 |
1986-07-01 |
Ortho Diagnostic Systems, Inc. |
Histidine stabilized immunoglobulin and method of preparation
|
US6673347B1
(en)
|
1986-04-30 |
2004-01-06 |
Gryphon Therapeutics |
Polypeptide and protein derivatives and process for their preparation
|
GB8628104D0
(en)
|
1986-11-25 |
1986-12-31 |
Connaught Lab |
Pasteurization of immunoglobin solutions
|
DE3640513A1
(de)
|
1986-11-27 |
1988-06-09 |
Biotest Pharma Gmbh |
Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
|
JP2547556B2
(ja)
|
1987-02-06 |
1996-10-23 |
株式会社 ミドリ十字 |
r−グロブリンの液状製剤
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
US5395760A
(en)
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
DK0417563T3
(da)
|
1989-09-12 |
2000-11-06 |
Hoffmann La Roche |
TNF-bindende proteiner
|
DE3939346A1
(de)
|
1989-11-29 |
1991-06-06 |
Behringwerke Ag |
Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
|
US5945098A
(en)
|
1990-02-01 |
1999-08-31 |
Baxter International Inc. |
Stable intravenously-administrable immune globulin preparation
|
US5177194A
(en)
|
1990-02-01 |
1993-01-05 |
Baxter International, Inc. |
Process for purifying immune serum globulins
|
GB9017002D0
(en)
|
1990-08-02 |
1990-09-19 |
Health Lab Service Board |
Improved method for the purification of erwina l-asparaginase
|
JP3179538B2
(ja)
|
1990-12-11 |
2001-06-25 |
ノバルティス アクチエンゲゼルシャフト |
安定なヒトカルシトニンの水性溶液
|
US5110910A
(en)
|
1991-03-25 |
1992-05-05 |
Miles Inc. |
Virucidal euglobulin precipitation
|
US5256571A
(en)
|
1991-05-01 |
1993-10-26 |
Cytyc Corporation |
Cell preservative solution
|
CA2126182C
(en)
|
1991-12-20 |
2001-07-17 |
Man S. Co |
Humanized antibodies reactive with gpiib/iiia
|
US6004555A
(en)
|
1992-03-05 |
1999-12-21 |
Board Of Regents, The University Of Texas System |
Methods for the specific coagulation of vasculature
|
US5298410A
(en)
|
1993-02-25 |
1994-03-29 |
Sterling Winthrop Inc. |
Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
|
US5484892A
(en)
|
1993-05-21 |
1996-01-16 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
|
DE4344824C1
(de)
|
1993-12-28 |
1995-08-31 |
Immuno Ag |
Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
|
GB9401448D0
(en)
|
1994-01-26 |
1994-03-23 |
Ciba Geigy Ag |
Stable dry powders
|
US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
AU3272695A
(en)
|
1994-08-12 |
1996-03-07 |
Immunomedics Inc. |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
BRPI9715219B8
(pt)
|
1996-02-09 |
2015-07-07 |
Abbvie Biotechnology Ltd |
Vetor recombinante de expressão, e célula hospedeira procariótica.
|
TWI240627B
(en)
|
1996-04-26 |
2005-10-01 |
Chugai Pharmaceutical Co Ltd |
Erythropoietin solution preparation
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
KR20000067911A
(ko)
|
1996-07-18 |
2000-11-25 |
씨에스엘 리미티드 |
면역글로불린 용액의 저온살균방법
|
TW491855B
(en)
|
1996-08-07 |
2002-06-21 |
Csl Ltd |
Purification of immunoglobulins
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US5886154A
(en)
|
1997-06-20 |
1999-03-23 |
Lebing; Wytold R. |
Chromatographic method for high yield purification and viral inactivation of antibodies
|
JP3679406B2
(ja)
|
1998-05-20 |
2005-08-03 |
協和醗酵工業株式会社 |
遺伝子組換え抗体
|
US6436897B2
(en)
|
1998-06-01 |
2002-08-20 |
Celtrix Pharmaceuticals, Inc. |
Pharmaceutical formulations for IGF/IGFBP
|
DK2272870T3
(da)
|
1998-06-09 |
2013-08-05 |
Csl Behring Ag |
Fremgangsmåde til fremstilling af immunoglobuliner med henblik på intravenøs indgivelse og andre immunoglobulin-lignende produkter.
|
US6610206B1
(en)
|
1998-10-20 |
2003-08-26 |
Advanced Renal Technologies |
Buffered compositions for dialysis
|
IL127127A0
(en)
|
1998-11-18 |
1999-09-22 |
Peptor Ltd |
Small functional units of antibody heavy chain variable regions
|
US7294481B1
(en)
|
1999-01-05 |
2007-11-13 |
Immunex Corporation |
Method for producing recombinant proteins
|
KR20010101987A
(ko)
|
1999-02-03 |
2001-11-15 |
스티븐 엠. 오드레 |
면역 반응과 관련된 신규한 폴리펩티드
|
DK1165119T3
(da)
|
1999-04-08 |
2003-12-15 |
Genentech Inc |
Sammensætning baseret på modsat ladede polypeptider
|
BR0010665A
(pt)
|
1999-04-09 |
2004-03-09 |
Ortho Mcneil Pharm Inc |
ComposiçÈes farmacêuticas de eritropoietina
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
AU4363200A
(en)
|
1999-04-19 |
2000-11-02 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical desorders
|
US20010021380A1
(en)
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
PL211886B1
(pl)
|
1999-10-04 |
2012-07-31 |
Novartis Vaccines & Diagnostic |
Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję
|
AU768324B2
(en)
|
1999-12-14 |
2003-12-11 |
Genentech Inc. |
TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
|
JP2004500063A
(ja)
|
1999-12-16 |
2004-01-08 |
アムジェン インコーポレイテッド |
Tnfr/opg様分子およびその使用
|
WO2001058473A1
(en)
|
2000-02-10 |
2001-08-16 |
Wyeth |
Method of treating or inhibiting cellular injury or cell death
|
DE60028830T2
(de)
|
2000-02-16 |
2007-01-18 |
Genentech, Inc., South San Francisco |
Anti-april antikörper und hybridomazellen
|
EP1304376A4
(en)
|
2000-07-25 |
2004-12-29 |
Takeda Chemical Industries Ltd |
PROCESS FOR PRODUCING RECOMBINANT PROTEIN
|
AU2001276737A1
(en)
|
2000-08-04 |
2002-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Protein injection preparations
|
ES2644275T3
(es)
|
2000-08-11 |
2017-11-28 |
Chugai Seiyaku Kabushiki Kaisha |
Preparaciones estabilizadas que contienen anticuerpos
|
DK1324776T4
(en)
|
2000-10-12 |
2018-05-28 |
Genentech Inc |
CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
|
MXPA03005327A
(es)
|
2000-12-14 |
2004-12-03 |
Fujisawa Pharmaceutical Co |
Anticuerpos anti-cd28 silenciados y el uso de estos.
|
US6693173B2
(en)
|
2000-12-26 |
2004-02-17 |
Alpha Therapeutic Corporation |
Method to remove citrate and aluminum from proteins
|
CN1854157B
(zh)
|
2001-01-05 |
2013-01-02 |
辉瑞大药厂 |
胰岛素样生长因子i受体的抗体
|
ES2184594B1
(es)
|
2001-01-17 |
2004-01-01 |
Probitas Pharma Sa |
Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
|
HUP0303246A2
(hu)
|
2001-02-23 |
2003-12-29 |
Immunex Corporation |
Aktív fehérjék fokozott kinyerése
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
JP2004521474A
(ja)
|
2001-06-25 |
2004-07-15 |
コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ |
高圧ガス放電ランプおよび高圧ガス放電ランプの製造方法
|
JP4212470B2
(ja)
|
2001-06-26 |
2009-01-21 |
アムジェン フレモント インク. |
Opglへの抗体
|
BR0212136A
(pt)
*
|
2001-08-23 |
2004-12-07 |
Genmab As |
Anticorpo monoclonal humano isolado, métodos para inibir a produção de tnfa em células t ou monócitos e a proliferação de célula t, hibridoma, transfectoma, animal não humano transgênico, método para produzir um anticorpo monoclonal humano, composição farmacêutica, métodos para tratar ou prevenir um distúrbio mediado pela il-15 humana, a psorìase e a artrite reumatóide, método para diagnosticar uma doença, ácido nucleico, e, vetor de expressão
|
US7247304B2
(en)
|
2001-08-23 |
2007-07-24 |
Genmab A/S |
Methods of treating using anti-IL-15 antibodies
|
IL159422A0
(en)
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
ATE556591T1
(de)
|
2001-11-08 |
2012-05-15 |
Abbott Biotherapeutics Corp |
Stabile pharmazeutische flüssigformulierung von igg-antikörpern
|
US20030143603A1
(en)
|
2001-11-30 |
2003-07-31 |
Jill Giles-Komar |
Anti-TNF antibodies, compositions, methods and uses
|
MXPA04006053A
(es)
|
2001-12-21 |
2005-03-31 |
Immunex Corp |
Metodos para purificacion de proteina.
|
EP3192528A1
(en)
|
2002-02-14 |
2017-07-19 |
Chugai Seiyaku Kabushiki Kaisha |
Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
|
CA2476776A1
(en)
|
2002-02-21 |
2003-09-04 |
Duke University |
Reagents and treatment methods for autoimmune diseases
|
PL215168B1
(pl)
|
2002-02-27 |
2013-10-31 |
Immunex Corp |
Formulacja polipeptydowa
|
AU2003220529B2
(en)
|
2002-03-27 |
2006-09-07 |
Immunex Corporation |
Methods for increasing polypeptide production
|
JP4761710B2
(ja)
|
2002-04-05 |
2011-08-31 |
アムジェン インコーポレイテッド |
選択的opgl経路インヒビターとしてのヒト抗opgl中和抗体
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
JP4319979B2
(ja)
|
2002-04-26 |
2009-08-26 |
ジェネンテック・インコーポレーテッド |
タンパク質の非アフィニティ精製
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
CA2490423A1
(en)
|
2002-06-21 |
2003-12-31 |
Biogen Idec Inc. |
Buffered formulations for concentrating antibodies and methods of use thereof
|
PL218992B1
(pl)
|
2002-07-19 |
2015-02-27 |
Abbott Biotech Ltd |
Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
DE60326012D1
(de)
|
2002-11-01 |
2009-03-12 |
Bayer Healthcare Llc |
Verfahren zur Konzentration von Proteinen
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
US7511012B2
(en)
|
2002-12-20 |
2009-03-31 |
Amgen Inc. |
Myostatin binding agents
|
BRPI0408317A
(pt)
|
2003-03-14 |
2006-03-07 |
Pharmacia Corp |
anticorpos do receptor de igf-i para o tratamento de cáncer
|
LT2335725T
(lt)
|
2003-04-04 |
2017-01-25 |
Genentech, Inc. |
Didelės koncentracijos antikūno ir baltymo kompozicijos
|
WO2004104021A2
(en)
|
2003-05-14 |
2004-12-02 |
Dow Corning Corporation |
Controlled release of active agents utilizing repeat sequence protein polymers
|
US7354578B2
(en)
|
2003-06-06 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with VEGF inhibitors
|
ES2315664T3
(es)
|
2003-06-30 |
2009-04-01 |
Domantis Limited |
Anticuerpos de dominio unico (dab) pegilados.
|
CA2543982C
(en)
|
2003-11-07 |
2013-01-08 |
Immunex Corporation |
Antibodies that bind interleukin-4 receptor
|
EP1532983A1
(en)
|
2003-11-18 |
2005-05-25 |
ZLB Bioplasma AG |
Immunoglobulin preparations having increased stability
|
CN1953768B
(zh)
|
2004-02-12 |
2010-10-13 |
默克专利有限公司 |
抗-egfr抗体的高浓缩液体制剂
|
US20070292346A1
(en)
|
2004-03-25 |
2007-12-20 |
Rong Fan |
Lng105 Antibody Composition and Methods of Use, and Use of Lng105 to Assess Lung Cancer Risk
|
MXPA06012992A
(es)
|
2004-05-12 |
2007-02-12 |
Baxter Int |
Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
|
JPWO2006003999A1
(ja)
|
2004-07-05 |
2008-07-31 |
財団法人化学及血清療法研究所 |
ヒト抗ヒトb7rp−1抗体およびその抗体フラグメント
|
JP5015774B2
(ja)
*
|
2004-07-29 |
2012-08-29 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ジフルオロ置換複素環化合物および液晶媒体における構成要素としてのその使用
|
TW200621282A
(en)
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
US7300773B2
(en)
|
2004-08-27 |
2007-11-27 |
Wyeth Research Ireland Limited |
Production of TNFR-Ig
|
EP1685161A1
(en)
|
2004-08-30 |
2006-08-02 |
Lonza Biologics plc |
Affinity- plus ion exchange-chromatography for purifying antibodies
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
WO2006064373A2
(en)
|
2004-12-16 |
2006-06-22 |
Genzyme Polyclonals S.A.S. |
Methods of purifying immunologlobulins
|
JP4498939B2
(ja)
|
2005-02-01 |
2010-07-07 |
東京応化工業株式会社 |
ポジ型レジスト組成物およびレジストパターン形成方法
|
US8597709B2
(en)
|
2005-04-12 |
2013-12-03 |
Inovobiologic Inc. |
Dietary supplement and methods of use
|
EP1909831A4
(en)
|
2005-06-14 |
2013-02-20 |
Amgen Inc |
PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070049732A1
(en)
|
2005-09-01 |
2007-03-01 |
Zurlo Eugene J |
Ultra-high yield intravenous immune globulin preparation
|
US8241692B2
(en)
|
2005-09-21 |
2012-08-14 |
Burcon Nutra Science (MB) Corp. |
Preparation of canola protein isolate involving isoelectric precipitation
|
US8067350B2
(en)
|
2005-12-15 |
2011-11-29 |
Kimberly-Clark Worldwide, Inc. |
Color changing cleansing composition
|
US20070202051A1
(en)
|
2006-02-10 |
2007-08-30 |
Pari Gmbh |
Aerosols for sinunasal drug delivery
|
NZ571757A
(en)
|
2006-04-21 |
2012-01-12 |
Novartis Ag |
Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
|
AU2007240732B2
(en)
|
2006-04-21 |
2013-07-04 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
EP2059523A2
(en)
|
2006-09-15 |
2009-05-20 |
Barofold, Inc. |
High pressure treatment of proteins for reduced immunogenicity
|
KR20150002896A
(ko)
|
2006-10-27 |
2015-01-07 |
애브비 바이오테크놀로지 리미티드 |
결정형 항-hTNF알파 항체
|
MX2009006594A
(es)
|
2006-12-21 |
2009-08-12 |
Amgen Inc |
Formulaciones de ph regulado y estables que contienen polipeptidos.
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
SG10201604258YA
(en)
|
2007-11-30 |
2016-07-28 |
Abbvie Biotechnology Ltd |
Anti-tnf antibody formulations
|
BRPI0908361A2
(pt)
*
|
2008-02-07 |
2015-04-07 |
Amgen Inc |
Seringas previamente cheias contendo composição e métodos de preparação das mesmas e de estabilização de agente de ligação específico em composição.
|
CA3142745A1
(en)
|
2008-05-20 |
2009-11-26 |
Avant Medical Corp. |
Autoinjector system
|
US8052645B2
(en)
|
2008-07-23 |
2011-11-08 |
Avant Medical Corp. |
System and method for an injection using a syringe needle
|
US8177749B2
(en)
|
2008-05-20 |
2012-05-15 |
Avant Medical Corp. |
Cassette for a hidden injection needle
|
CN102159204B
(zh)
*
|
2008-09-19 |
2015-04-01 |
辉瑞公司 |
稳定的液体抗体制剂
|
EP3011953A1
(en)
*
|
2008-10-29 |
2016-04-27 |
Ablynx N.V. |
Stabilised formulations of single domain antigen binding molecules
|
KR20110128333A
(ko)
|
2009-03-06 |
2011-11-29 |
제넨테크, 인크. |
항체 제제
|
US20110070227A1
(en)
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
PL2637690T3
(pl)
|
2010-11-11 |
2017-03-31 |
Abbvie Biotechnology Ltd |
Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu
|
US9173999B2
(en)
|
2011-01-26 |
2015-11-03 |
Kaleo, Inc. |
Devices and methods for delivering medicaments from a multi-chamber container
|
CA3021845C
(en)
|
2011-04-20 |
2022-03-29 |
Amgen Inc. |
Autoinjector apparatus
|
US9453067B2
(en)
*
|
2011-04-20 |
2016-09-27 |
Sandoz Ag |
Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
|
UY34105A
(es)
*
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
MX358137B
(es)
|
2011-07-01 |
2018-08-06 |
Biogen Idec Inc |
Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
|
HUE045624T2
(hu)
*
|
2011-10-18 |
2020-01-28 |
Coherus Biosciences Inc |
Magnézium ionokkal stabilizált etanercept készítmények
|
JP2015519382A
(ja)
*
|
2012-06-12 |
2015-07-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
治療用抗体のための医薬処方物
|
US8920374B2
(en)
|
2012-07-05 |
2014-12-30 |
Unitract Syringe Pty Ltd |
Drive control mechanisms and automatic injectors for injectable cartridges
|
PE20150762A1
(es)
|
2012-07-09 |
2015-06-20 |
Coherus Biosciences Inc |
Formulaciones de etanercept que muestran una marcada reduccion de la cantidad de particulas subvisibles
|
JP2015533797A
(ja)
*
|
2012-09-11 |
2015-11-26 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
高純度および優れた収率の正確に折り畳まれたエタネルセプト
|
KR102132050B1
(ko)
*
|
2012-10-26 |
2020-07-10 |
루핀 아틀란티스 홀딩스 에스에이 |
티엔에프알에프씨 융합 단백질의 안정한 약학 조성물
|
EP2919812A4
(en)
*
|
2012-11-19 |
2016-05-18 |
Merck Sharp & Dohme |
Liquid formulations for TNFR: FC fusion proteins
|
JP6026002B2
(ja)
*
|
2012-11-27 |
2016-11-16 |
アルテオジェン インコーポレイテッド |
タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物
|
US9452138B2
(en)
|
2012-12-28 |
2016-09-27 |
Abbott Cardiovascular Systems Inc. |
Delivery of biologic therapeutics
|
TWI580452B
(zh)
|
2013-03-15 |
2017-05-01 |
安美基公司 |
用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
AU2014261477A1
(en)
|
2013-05-02 |
2015-11-19 |
Mabxience, S.A. |
Alternative formulations for TNFR: Fc fusion polypeptides
|
CN105611938A
(zh)
*
|
2013-10-24 |
2016-05-25 |
免疫医疗有限责任公司 |
稳定的水性抗体配制品
|
US9700595B2
(en)
|
2013-11-29 |
2017-07-11 |
Ares Trading Sa |
Liquid formulation of a fusion protein comprising TNFR and Fc region
|
EP2975050B1
(en)
|
2014-07-18 |
2019-05-29 |
Sandoz Ag |
Quantification of misfolded TNFR2:Fc
|
EP3733228B1
(en)
|
2014-08-28 |
2024-03-06 |
UNL Holdings LLC |
Sensor systems for drug delivery devices
|
PT3185934T
(pt)
|
2014-08-28 |
2018-10-19 |
Unl Holdings Llc |
Sensores de pele para dispositivos de administração de medicamento
|
US10959939B2
(en)
|
2014-12-22 |
2021-03-30 |
Ares Trading S.A. |
Liquid pharmaceutical composition of etanercept with lysine and proline
|
WO2016149139A1
(en)
|
2015-03-13 |
2016-09-22 |
Samsung Bioepis Co., Ltd. |
Anti-tnf-alpha polypeptide composition and use thereof
|
US9763976B1
(en)
|
2016-08-02 |
2017-09-19 |
Zo Skin Health, Inc. |
Composition and method for treating skin conditions
|
US20180110856A1
(en)
|
2016-10-21 |
2018-04-26 |
Amgen Inc. |
Pharmaceutical Formulations and Methods of Making the Same
|